Clinical Trials in the USA / NCT06926920
Recruiting
Phase 1/2
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
NCT06926920 · tracked via the Priya Life Science USA tracker
Condition(s) studied
Triple Negative Breast Cancer
Investigational drug(s) / intervention(s)
Sacituzumab Govitecan-hziy (SG): Administered intravenously
Study summary
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC).
The primary objectives of this study are to assess the safety and tolerability of SG given at alternate dose and schedule, to assess the effect on objective response rate (ORR) and progression-free survival (PFS).
Eligibility
Key Inclusion Criteria:
* Individuals assigned male or female at birth, 18 years of age or older, able to understand and give written informed consent.
* Histologically or cytologically locally confirmed TNBC.
* Phase 1: Individuals with unresectable, locally advanced or metastatic TNBC who are refractory to or relapsed after at least one prior standard-of-care chemotherapy regimen or systemic therapy given for locally advanced or metastatic disease.
* Phase 2: Individuals with unresectable, locally advanced or metastatic TNBC who have not received previous systemic therapy for advanced disease.
* Phase 2: Tumors must be PD-L1 negative, defined as tumor PD-L1 combined positive score (CPS) \< 10 using the PD-L1 immunohistochemistry (IHC) 22C3 assay. Alternatively, individuals with tumor CPS ≥ 10 will be eligible if they received an anti-PD-(L)1 agent (ie, checkpoint inhibitor) in the adjuvant or neoadjuvant setting or if they cannot be treated with an anti-PD-(L)1 agent. due to a comorbidity.
* Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotype status.
During Phase 1 safety run-in, individuals must be UGT1A1 wild-type.
After Phase 1 safety run-in, individuals with any UGT1A1 genotype may be eligible.
* Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) according to RECIST Version 1.1 criteria.
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
* Adequate hematologic counts within 2 weeks prior to enrollment.
* Adequate hepatic and renal function.
Key Exclusion Criteria:
* Prior treatment with a topoisomerase 1 inhibitor or antibody-drug conjugate (ADC) containing a topoisomerase inhibitor.
* Prior treatment with a trophoblast cell-surface antigen 2 (Trop-2)-directed ADC.
Note: Other protocol defined Inclusion/Exclusion criteria will apply.
Primary outcome measure(s)
- Phase 1: Percentage of Participants Experiencing Dose-Limiting Toxicities (DLTs) — First dose up to 28 days
- Phase 1 and 2: Percentages of Participants Experiencing Adverse Events (AEs) — First dose up to 30 days post last dose (Up to 3 years)
- Phases 1 and 2: Percentages of Participants Experiencing Laboratory Abnormalities — First dose up to 30 days post last dose (Up to 3 years).
- Phases 1 and 2: Percentages of Participants Experiencing AEs Leading to Dose Reductions, Dose Interruptions, and Treatment Discontinuations — First dose up to 30 days post last dose (Up to 3 years).
- Phases 1 and 2: Objective Response Rate (ORR) — Up to 9 months
ORR is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR) that is confirmed at least 4 weeks after initial documentation of response as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. - Phase 2: Progression-Free Survival (PFS) — Up to 9 months
PFS is defined as the time from the date of the first SG dose until the date of progressive disease (PD) as assessed by the investigator according to RECIST Version 1.1, or death from any cause, whichever occurs first.
Trial sites (16)
| Facility | City | Region | Status |
|---|---|---|---|
| Los Angeles Cancer Network (LACN) - Good Sam | Los Angeles | California | Recruiting |
| Winship Cancer Institute - Emory University | Atlanta | Georgia | Recruiting |
| The University of Kansas Hospital | Westwood | Kansas | Recruiting |
| Siteman Cancer Center | St Louis | Missouri | Recruiting |
| West Cancer Centre | Germantown | Tennessee | Recruiting |
| SCRI Oncology Partners | Nashville | Tennessee | Recruiting |
| Tennessee Oncology, PLLC | Nashville | Tennessee | Recruiting |
| Texas Oncology - DFW | Dallas | Texas | Recruiting |
| Virginia Oncology Associates | Norfolk | Virginia | Recruiting |
| St. Vincent's Hospital - Kinghorn Cancer Center | Darlinghurst | New South Wales | Recruiting |
| Sunshine Coast University Private Hospital | Birtinya | Queensland | Recruiting |
| John Flynn Private Hospital | Tugun | Queensland | Recruiting |
| Seoul National University Hospital | Seoul | South Korea | Recruiting |
| Severance Hospital, Yonsei University Health System | Seoul | South Korea | Not Yet Recruiting |
| Asan Medical Center | Seoul | South Korea | Recruiting |
| Samsung Medical Center | Seoul | South Korea | Recruiting |
More Gilead Sciences trials in the USA
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
Active, not recruiting
Other trials for the same condition
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06926920 on ClinicalTrials.gov ↗ ← All trials in the USA